

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-22. (Canceled)

1 23 (Currently amended). An isolated antibody or antigen binding fragment thereof which:

- (a) specifically binds a factor IX/IXa Gla domain; and
- (b) comprises a heavy chain and a light chain variable region further wherein:
  - (i) the heavy chain variable region comprises a CDR1 which is SEQ ID NO:10, a CDR2 which is SEQ ID NO:11 and a CDR3 which is SEQ ID NO:12; and
  - (ii) the light chain variable region comprises an -le a CDR1 which is SEQ ID NO:13, and -le a CDR2 which is SEQ ID NO:14, and an -le a CDR3 which is SEQ ID NO:15.

2 24 (Previously presented). A composition comprising the antibody or antigen binding fragment of Claim 23 and a carrier, excipient or stabilizer.

3 25 (Previously presented). The composition of Claim 24, wherein the carrier, excipient or stabilizer is pharmaceutically-acceptable.

4 26 (Previously presented). The composition of Claim 25, which is sterile.

5 27 (Previously presented). The composition of Claim 26 further comprising a thrombolytic agent.

6 28 (Previously presented). The composition of Claim 27 wherein the thrombolytic agent is tissue plasminogen activator.

7 29 (Previously presented). The composition of Claim 27 wherein the thrombolytic agent is streptokinase.

8 30 (Previously presented). The composition of Claim 27 wherein the thrombolytic agent is urokinase.

Amend. dated August 22, 2005

Response to Office Action mailed on: April 20, 2005

9 ~~31~~ (Previously presented). The composition of Claim ~~21~~ <sup>5</sup> wherein the thrombolytic agent is an isolated streptokinase plasminogen.

10 ~~32~~ (Previously presented). The composition of Claim ~~26~~ <sup>4</sup> which is lyophilized.

11 ~~33~~ (Previously presented). The composition of Claim ~~26~~ <sup>4</sup> which is liquid.

12 ~~34~~ (Previously presented). The composition of Claim ~~27~~ <sup>5</sup> which is lyophilized.

13 ~~35~~ (Previously presented). The composition of Claim ~~21~~ <sup>5</sup> which is liquid.

14 ~~36~~ (Previously presented). An article of manufacture comprising:

(a) a container;

(b) a label on said container; and

(c) a composition comprising an antibody or antibody fragment of Claim ~~23~~ <sup>1</sup> within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

15 ~~37~~ (Previously presented). An article of manufacture comprising:

(a) a container;

(b) a label on said container; and

(c) the composition of Claim ~~26~~ <sup>4</sup> within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

16 ~~38~~ (Previously presented). An article of manufacture comprising:

Amend. dated August 22, 2005

Response to Office Action mailed on: April 20, 2005

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim <sup>5</sup>~~21~~ within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

<sup>17</sup>  
~~39~~ (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim <sup>6</sup>~~28~~ within said container; wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

<sup>18</sup>  
~~40~~ (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim <sup>7</sup>~~29~~ within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

<sup>19</sup>  
~~41~~ (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim <sup>8</sup>~~30~~ within said container;

Amend. dated August 22, 2005

Response to Office Action mailed on: April 20, 2005

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

20

42 (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim 31 within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.